ReviewBest practice & research. Clinical haematology2018
CAR T cell therapy for B-cell lymphomas.
Review in Best practice & research. Clinical haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Cancer biology & medicine · 2023Guideline
- Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Targeting CCR7-KMT2D enhances CAR-T cell efficacy by suppressing therapy-induced senescence in B-cell non-Hodgkin lymphoma.BMC medicine · 2026Article
- Article
- Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives.European journal of haematology · 2025Review
- Selectively expressed RNA molecules as a versatile tool for functionalized cell targeting.Nature communications · 2025Article
- Case Report: subhepatic appendicitis complicated by hepatic abscess as the initial presentation of primary diffuse large B-cell lymphoma of the appendix: first reported case.Frontiers in oncology · 2025Article
- Article
- Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma.Mini reviews in medicinal chemistry · 2024Review
- Unraveling the complexity of follicular lymphoma: insights and innovations.American journal of cancer research · 2024Review
- Intestinal barrier functions in hematologic and oncologic diseases.Journal of translational medicine · 2023Review
- Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells.Frontiers in immunology · 2023Article
- The Role of the Research Advanced Practice Provider in CAR T-Cell Clinical Trials.Journal of the advanced practitioner in oncology · 2023Review
- Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?Cancers · 2022Review
- Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.Viruses · 2022Review
- Immunophenotypic Landscape and Prognosis-Related mRNA Signature in Diffuse Large B Cell Lymphoma.Frontiers in genetics · 2022Article
- Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas.Current treatment options in oncology · 2022Review
- Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients.Cancers · 2021Article
- Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells.The Journal of veterinary medical science · 2021Article
- [Effects of glucocorticoids on the proliferation of CD19 CAR-T cells targeting B-cell tumor cell lines].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited alternatives for cure. Adoptive therapy with chimeric antigen receptor (CAR) T-cells is a new paradigm for effective treatment of poor prognosis lymphomas. Here we review the biology of poor risk DLBCL and FL, the rationale for CAR T-cell therapy in malignant lymphoma and the efficacy/toxicity profile of CD19 directed CAR T cell therapy for DLBCL and FL from early single center studies to multicenter/global clinical trial with different CAR T cell constructs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.